Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mirum Pharmaceuticals, Inc.

45.05
-0.9400-2.04%
Post-market: 45.050.00000.00%16:36 EDT
Volume:394.62K
Turnover:17.81M
Market Cap:2.21B
PE:-24.34
High:45.71
Open:45.09
Low:44.00
Close:45.99
Loading ...

Mirum Pharmaceuticals Is Maintained at Outperform by Baird

Dow Jones
·
27 Feb

Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ...

GuruFocus.com
·
27 Feb

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Mirum Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Mirum Pharmaceuticals Q4 2024 GAAP EPS $(0.49) Misses $(0.28) Estimate, Sales $99.430M Beat $96.606M Estimate

Benzinga
·
27 Feb

Mirum Pharmaceuticals Q4 Sales $99.430M Beat $96.606M Estimate

Benzinga
·
27 Feb

BRIEF-Mirum Pharmaceuticals Q4 Operating Income USD -24.222 Million

Reuters
·
27 Feb

Mirum Pharmaceuticals Q4 Product Sales USD 99.43 Million

THOMSON REUTERS
·
27 Feb

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Business Wire
·
27 Feb

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

Zacks
·
26 Feb

Mirum Pharmaceuticals Price Target Maintained With a $74.00/Share by Citizens Capital Markets

Dow Jones
·
24 Feb

Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug

MT Newswires Live
·
24 Feb

Mirum Pharmaceuticals announces FDA approval for Ctexli tablets

TIPRANKS
·
24 Feb

Mirum Pharmaceuticals Inc - Ctexli Granted FDA Orphan Drug Exclusivity for Ctx

THOMSON REUTERS
·
24 Feb

Mirum Pharmaceuticals Inc - Ctexli Available Through Mirum Access Plus, Mirum’s Patient Support Program

THOMSON REUTERS
·
24 Feb

Mirum’s Ctexli™ (Chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (Ctx)

THOMSON REUTERS
·
24 Feb